<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sera from healthy individuals and patients with <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, or other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> were examined for their capacity to neutralize Epstein-Barr virus (EBV)-induced DNase activity </plain></SENT>
<SENT sid="1" pm="."><plain>Sera were found that neutralized the EBV DNase but not <z:e sem="disease" ids="C0019348" disease_type="Disease or Syndrome" abbrv="">herpes simplex</z:e> virus type 1 or type 2 DNases, and vice versa </plain></SENT>
<SENT sid="2" pm="."><plain>Sera from 46 of the 49 patients with nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> examined (94%) neutralized &gt; 6 units of EBV DNase per ml of serum </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, only 19% of 47 patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 12% of 183 patient with other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, 4% of 58 patients with <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, and none of 101 healthy individuals had such levels of neutralizing activity </plain></SENT>
<SENT sid="4" pm="."><plain>The neutralizing factor was found in the IgG fraction derived from nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> sera </plain></SENT>
<SENT sid="5" pm="."><plain>There was no correlation between the concentration of these antibodie and the titers of IgG ad IgA antibodies to the EBV capsid antigen, the early antigen complex, or the EBV-associated nuclear antigen </plain></SENT>
</text></document>